Virobay Facts

2014 – Virobay completes $8 million Series B preferred stock financing more

2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

more

Publications and Presentations

Nature Cell Biology 2014, Aug 3

Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ, Massague J, Leslie CS, Joyce JA.

Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S

Poster Presentation, AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, November 2011, San Francisco, USA

Leslie J. Holsinger, Alysia Ondoua-Lozano, Jade Rodriguez, Katherine Hanlon, Edward J. Bilsky, Joshua Havelin, Jeffrey M. Dener, Robert Booth, Todd W. Vanderah

Efficacy of a Spectrum-Selective Cathepsin Inhibitor in a Mouse Model of Bone Cancer

Poster Presentation, AASLD Annual Meeting, November 2010, Boston, USA

Leslie J. Holsinger, Dion F. Coakley, Jeffrey M. Dener, Michael J. Green, Robert Booth, Stacie A. Dalrymple

Efficacy of a Reversible Cathepsin B Inhibitor in a Rodent Model of Liver Fibrosis and Human Pharmacokinetic Profile

Poster Presentation, Pain 2010: Bench to Bedside Frontiers of Clinical Investigation Symposium, October 2010, San Diego, CA. USA

Leslie J. Holsinger, John Grist, Anna K. Clark, Robert Booth, Marzia Malcangio, Stacie A. Dalrymple

Systemic Inhibition of Cathepsin S Attenuates Hypersensitivity in Animal Models of Neuropathic and Inflammatory Pain

Biochimie 2010 Nov;92(11):1618-24

Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA

Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model

Poster Presentation, Society for Neuroscience, October 2009, Chicago, USA

Stacie A. Dalrymple, John Grist, Anna K. Clark, and Marzia Malcangio

Systemic Inhibition of Cathepsin S Attenuates Vincristine-Induced Neuropathic Hypersensitivity

Poster Presentation, Society of Investigative Dermatology, May 2009, Montreal, Canada

Leslie J. Holsinger, Simonetta Mocci, John O. Link, Kyle Elrod ,Michael J.  Green, Robert Booth, Stacie A. Dalrymple

Characterization of VBY-129, a Cathepsin S Inhibitor Efficacious in a Mouse Model of Psoriasis

Oral Presentation: The American Pain Society Annual Meeting, May 2009, San Diego CA. USA

Stacie A. Dalrymple, Nigel Calcutt, Teresa Mixcoatl-Zecuatl, John Grist, Marzia Malcangio, John Link

A selective cathepsin S inhibitor, VBY-285, reverses allodynia in a rat model of diabetic neuropathy